KAPA · Insider Trading
Kairos Pharma, Ltd.
Every open-market purchase and sale reported by KAPA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-30 | Neil Bhowmick | Chief Scientific Officer | A | +171,756 | — |
| 2025-12-23 | Hyun W. Bae | Director | A | +29,084 | — |
| 2025-11-26 | Hansoo Michael Keyoung | Director | A | +29,084 | — |
| 2025-11-26 | John S Yu | CEO and Chairman | A | +190,840 | — |
| 2025-11-26 | Ramachandran Murali | VP of Research and Development | A | +152,672 | — |
| 2025-11-26 | Rahul Singhvi | Director | A | +19,084 | — |
| 2025-11-26 | Doug Samuelson | Chief Financial Officer | A | +152,672 | — |
| 2025-04-07 | Neil Bhowmick | Chief Scientific Officer | A | +14,000 | — |
| 2025-02-24 | John S Yu | CEO and Chairman | A | +14,000 | — |
| 2025-02-24 | Ramachandran Murali | VP of Research and Development | A | +14,000 | — |
| 2024-11-25 | Ramachandran Murali | VP of Research and Development | Buy | +200 | +$318 |
| 2024-11-25 | Doug Samuelson | Chief Financial Officer | Buy | +2,500 | +$3.75K |
| 2024-11-21 | John S Yu | CEO and Chairman | Buy | +4,000 | +$5.76K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| John S Yu | CEO and Chairman | 792,382 | $442.55K |
| Neil Bhowmick | Chief Scientific Officer | 187,391 | $104.66K |
| Ramachandran Murali | VP of Research and Development | 42,790 | $23.90K |
| Doug Samuelson | Chief Financial Officer | 41,863 | $23.38K |
| Hyun W. Bae | Director | 7,755 | $4.33K |
| Rahul Singhvi | Director | 7,029 | $3.93K |
| Hansoo Michael Keyoung | Director | 1,429 | $798 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the KAPA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.